<DOC>
	<DOCNO>NCT01002820</DOCNO>
	<brief_summary>This study design provide ganaxolone patient derive significant benefit current treatment protocol 1042-0601 .</brief_summary>
	<brief_title>A Treatment Use Protocol Subjects Continuing From Open-label Extension 0601</brief_title>
	<detailed_description />
	<mesh_term>Epilepsy , Complex Partial</mesh_term>
	<mesh_term>Pregnanolone</mesh_term>
	<criteria>subject complete study visit previous protocol 10420601 deem eligible Investigator : major adverse event think drug relate derive benefit ganaxolone treatment properly inform nature risk study give write informed consent prior study entry must willing use medically acceptable method birth control female childbearing potential , negative qualitative serum pregnancy test significant medical surgical condition screen develops protocol participation might compromise hematologic , cardiovascular , pulmonary , renal , gastrointestinal , hepatic system , condition would place subject increase risk unwilling use doublebarrier method birth control submit serum pregnancy test history chronic noncompliance drug regimen females currently breastfeed AST ALT level great 3 time upper limit normal screen Inability withhold grapefruit grapefruit product study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>October 2015</verification_date>
	<keyword>Epileptic Seizures</keyword>
	<keyword>Seizure Disorder</keyword>
	<keyword>Seizures</keyword>
	<keyword>Convulsions</keyword>
	<keyword>Anticonvulsant</keyword>
	<keyword>Anticonvulsive</keyword>
	<keyword>Antiepileptic</keyword>
	<keyword>Ganaxolone</keyword>
</DOC>